AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- 4DMedical (4DX) renews and expands contract with Stanford’s 3DQ Lab
- Agreement includes cutting-edge lung imaging tech ahead of FDA clearance
- Enhanced U.S. research foothold supports momentum within ASX300 stocks
4DMedical Limited (ASX:4DX), a pioneering medical technology company, has announced a renewed and significantly broadened agreement with Stanford University’s prestigious 3D Quantitative Imaging Laboratory (3DQ Lab). This development marks another leap forward in 4DMedical’s global research collaborations and technology validation efforts.
The newly structured one-year subscription contract enables the lab to process up to 20,000 CT scan analysis jobs annually, reflecting increased demand and broader utility of 4DMedical’s advanced respiratory imaging solutions. Notably, this upgraded partnership now includes access to three of the company’s key technologies—CT:VQ™, CT LVAS™, and IQ-UIP™—expanding the lab’s capability for clinical and investigational work.
A particularly striking aspect of this expansion is Stanford’s decision to incorporate the CT:VQ™ platform into its research suite ahead of regulatory clearance from the U.S. Food and Drug Administration (FDA). This early adoption of a pre-approved technology from a leading research institution adds weight to the innovation's potential and supports its trajectory towards wider clinical adoption in the U.S.
4DMedical’s founder and CEO, Andreas Fouras, highlighted the importance of this partnership by describing Stanford’s 3DQ Lab as one of the world’s most influential centers in the field of medical imaging. The lab’s ongoing confidence and investment in 4DMedical’s product suite not only enhances the company’s visibility among global research communities but also accelerates the technology’s pathway to regulatory milestones and market scaling.
This announcement aligns with 4DMedical’s positioning among ASX300, underlining the company’s growing importance within Australia's broader investment and innovation landscape.
The expanded Stanford collaboration demonstrates a strong signal of global academic interest in 4DMedical’s unique lung imaging solutions and supports the company’s long-term mission of revolutionizing respiratory diagnostics. With the CT:VQ™ tool now under high-profile study and increasing its momentum toward FDA approval, 4DMedical continues to establish itself as a high-impact player within the ASX300 cohort and the broader medical imaging space.
